C4 Therapeutics (CCCC) Competitors $2.24 -0.06 (-2.40%) As of 02:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CCCC vs. IOVA, URGN, TLRY, TNGX, STOK, PRME, DNTH, PHAT, UPB, and XNCRShould you be buying C4 Therapeutics stock or one of its competitors? The main competitors of C4 Therapeutics include Iovance Biotherapeutics (IOVA), Urogen Pharma (URGN), Tilray Brands (TLRY), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Prime Medicine (PRME), Dianthus Therapeutics (DNTH), Phathom Pharmaceuticals (PHAT), Upstream Bio (UPB), and Xencor (XNCR). These companies are all part of the "pharmaceutical products" industry. C4 Therapeutics vs. Its Competitors Iovance Biotherapeutics Urogen Pharma Tilray Brands Tango Therapeutics Stoke Therapeutics Prime Medicine Dianthus Therapeutics Phathom Pharmaceuticals Upstream Bio Xencor C4 Therapeutics (NASDAQ:CCCC) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment. Does the media refer more to CCCC or IOVA? In the previous week, Iovance Biotherapeutics had 18 more articles in the media than C4 Therapeutics. MarketBeat recorded 19 mentions for Iovance Biotherapeutics and 1 mentions for C4 Therapeutics. C4 Therapeutics' average media sentiment score of 0.94 beat Iovance Biotherapeutics' score of 0.14 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Overall Sentiment C4 Therapeutics Positive Iovance Biotherapeutics Neutral Which has stronger earnings & valuation, CCCC or IOVA? C4 Therapeutics has higher earnings, but lower revenue than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$35.58M4.46-$105.32M-$1.47-1.52Iovance Biotherapeutics$212.68M4.94-$372.18M-$1.24-2.54 Is CCCC or IOVA more profitable? Iovance Biotherapeutics has a net margin of -176.49% compared to C4 Therapeutics' net margin of -259.60%. C4 Therapeutics' return on equity of -45.86% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-259.60% -45.86% -28.96% Iovance Biotherapeutics -176.49%-49.71%-39.18% Do insiders and institutionals have more ownership in CCCC or IOVA? 78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 8.7% of C4 Therapeutics shares are held by company insiders. Comparatively, 10.3% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, CCCC or IOVA? C4 Therapeutics has a beta of 2.94, indicating that its stock price is 194% more volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Do analysts rate CCCC or IOVA? C4 Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 436.91%. Iovance Biotherapeutics has a consensus price target of $12.22, suggesting a potential upside of 288.62%. Given C4 Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe C4 Therapeutics is more favorable than Iovance Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Iovance Biotherapeutics 1 Sell rating(s) 6 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryC4 Therapeutics beats Iovance Biotherapeutics on 9 of the 16 factors compared between the two stocks. Get C4 Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CCCC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CCCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CCCC vs. The Competition Export to ExcelMetricC4 TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$158.71M$3.04B$5.71B$9.51BDividend YieldN/A2.40%4.60%3.99%P/E Ratio-1.5221.1328.0720.02Price / Sales4.46338.95459.47103.02Price / CashN/A43.2336.5558.97Price / Book0.738.278.615.88Net Income-$105.32M-$55.19M$3.24B$258.50M7 Day Performance-3.66%5.50%3.83%2.03%1 Month Performance45.13%17.25%10.40%12.52%1 Year Performance-65.30%4.61%34.13%19.07% C4 Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CCCCC4 Therapeutics2.8577 of 5 stars$2.24-2.4%$12.00+436.9%-61.4%$158.71M$35.58M-1.52150Upcoming EarningsIOVAIovance Biotherapeutics4.6168 of 5 stars$2.01+7.5%$12.22+508.1%-64.0%$671.20M$164.07M-1.62500Analyst ForecastOptions VolumeGap UpHigh Trading VolumeURGNUrogen Pharma4.5082 of 5 stars$14.49+1.8%$32.86+126.8%+10.0%$668.13M$90.40M-4.56200TLRYTilray Brands1.8236 of 5 stars$0.66+13.1%$1.92+191.8%-60.7%$661.07M$788.94M-0.632,650Upcoming EarningsOptions VolumeTNGXTango Therapeutics1.6923 of 5 stars$6.09+2.7%$12.20+100.3%-31.9%$660.12M$40.99M-4.9990STOKStoke Therapeutics4.2453 of 5 stars$12.06+1.7%$24.75+105.2%-5.4%$658.48M$36.56M15.27100PRMEPrime Medicine3.853 of 5 stars$4.80+10.3%$10.08+110.1%-20.8%$645.57M$3.85M-2.34234Gap DownHigh Trading VolumeDNTHDianthus Therapeutics1.3859 of 5 stars$20.03-0.1%$53.00+164.6%-21.7%$644.17M$6.24M-6.9580Positive NewsPHATPhathom Pharmaceuticals4.3157 of 5 stars$9.06-1.3%$17.50+93.2%-21.0%$632.48M$55.25M-1.73110Positive NewsUPBUpstream Bio1.7818 of 5 stars$11.73+2.2%$56.50+381.7%N/A$631.00M$2.30M0.0038News CoverageXNCRXencor4.5069 of 5 stars$8.85+0.2%$28.00+216.4%-54.7%$629.85M$110.49M-2.89280Positive News Related Companies and Tools Related Companies Iovance Biotherapeutics Competitors Urogen Pharma Competitors Tilray Brands Competitors Tango Therapeutics Competitors Stoke Therapeutics Competitors Prime Medicine Competitors Dianthus Therapeutics Competitors Phathom Pharmaceuticals Competitors Upstream Bio Competitors Xencor Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CCCC) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CCCC Stock Alerts